Health Care

4463 posts
Magneto scan concept

Neurizon doses first patient with NUZ-001 in amyotrophic lateral sclerosis trial

Neurizon dosed its first patient in an ALS trial, with another 159 patients to come in…
AI image of money.

Profit-making Compumedics clocks record sales in H1FY26; SaaS revenue up +56%

Compumedics (ASX:CMP) has officia…
Close up of CSL sign on the office building in Melbourne, Victoria, Australia.

CSL profit drop only deepens what has already been grim reporting week

CSL Ltd has backed up its chaotic Tuesday – where the board dumped Paul McKenzie –…

Paradigm Biopharmaceuticals to boost oral treatment of osteoarthritis for animals

Paradigm Biopharmaceuticals (ASX: PAR) is co-developing a novel oral combination therapy for the treatment of osteoarthritis…
MEG scan concept AI gen

Compumedics snags sixth order for Orion LifeSpan at $4.2M heading to Shandong

Compumedics has inked a fresh $4.2M order to kick off CY26 with a sixth unit of…
A woman with a sign and a sad face

Last year’s anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in
Brain scan concept

Healthcare disruptor Compumedics clocks record sales in 1H FY26 at $33M; revenue up +32%

Compumedics has posted its highest-ever sales figure, netting $33M in the first half of FY26, also…
Chinese health market concept

Telix jumps on maiden Chinese application for prostate imaging agent, but short selling increasing

Telix Pharma’s (ASX:TLX) got the Chinese market locked in its sights with a maiden application for Illuccix, a prostate
FDA cpmce[t

Mesoblast dips on confusion around FDA advice on stem cells for back pain

Mesoblast (ASX:MSB) has seen its shares dip on Monday morning out the gate as some investors struggle to digest
Kuala Lumpur skyline

ReNerve jumps as flagship medtech approved in Malaysia, but gains pare in rush hour

ReNerve initially had a strong green run Thursday morning but by rush hour shares had pared…